ストックスクリーナーアプリを入手
5.61
8.63%
-0.53
アフターアワーズ：
5.72
0.11
+1.96%
前日終値:
$6.14
開ける：
$5.94
24時間の取引高:
1.14M
Relative Volume:
1.11
時価総額：
$437.08M
収益：
$14.79M
当期純損益:
$-102.44M
株価収益率:
-1.8454
EPS:
-3.04
ネットキャッシュフロー:
$-91.73M
1週間 パフォーマンス:
-10.81%
1か月 パフォーマンス:
-9.95%
6か月 パフォーマンス:
+2.00%
1年 パフォーマンス:
-2.60%
1日の値動き範囲:
$5.5239
$5.99
1週間の範囲:
$5.5239
$6.55
52週間の値動き範囲:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
名前
Solid Biosciences Inc
セクター
電話
617-337-4680
住所
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
Compare SLDB vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.61 | 478.37M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-04 | 開始されました | Needham | Buy |
| 2025-06-26 | 開始されました | Citigroup | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-13 | 開始されました | Wedbush | Outperform |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-15 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-06-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 再開されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | William Blair | Outperform |
| 2024-03-15 | 開始されました | Citigroup | Buy |
| 2024-03-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-07-12 | 開始されました | Piper Sandler | Neutral |
| 2021-05-27 | 開始されました | Jefferies | Buy |
| 2021-03-16 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2021-01-08 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 開始されました | Evercore ISI | Outperform |
| 2019-08-29 | ダウングレード | Citigroup | Neutral → Sell |
| 2019-08-19 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | ダウングレード | Goldman | Neutral → Sell |
| 2019-02-08 | アップグレード | Citigroup | Sell → Neutral |
| 2019-02-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 開始されました | Citigroup | Sell |
| 2018-09-06 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Solid Biosciences Inc (SLDB) 最新ニュース
SLDB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Solid Biosciences (SLDB) Stock Price, News & Analysis - MarketBeat
Biotech Sector Sustains After-Hours Trading Gains - Intellectia AI
Solid Biosciences (SLDB) Projected to Post Earnings on Thursday - MarketBeat
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences Inc. sponsors international muscular dystrophy conference in Rome - Traders Union
SLDB SEC FilingsSolid Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan
Solid Biosciences CTO Herzich sells $21k in shares By Investing.com - Investing.com South Africa
Solid Biosciences CEO Cumbo sells $96k in shares By Investing.com - Investing.com Canada
Solid Biosciences CTO Herzich sells $21k in shares - Investing.com India
Patterns Watch: What are Solid Biosciences Incs earnings expectationsMarket Activity Recap & Safe Entry Trade Signal Reports - baoquankhu1.vn
David Howton Sells 7,469 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CEO Sells $96,868.08 in Stock - MarketBeat
Solid Biosciences (NASDAQ:SLDB) Insider Jessie Hanrahan Sells 4,134 Shares - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) Director Sells 2,658 Shares of Stock - MarketBeat
Solid Biosciences CFO Tan sells $31k in shares - Investing.com Nigeria
Solid Biosciences CFO Tan sells $31k in shares By Investing.com - Investing.com Nigeria
Solid Biosciences COO Howton sells $43k in shares By Investing.com - Investing.com Nigeria
Solid Biosciences director’s wife sells $15k in shares By Investing.com - Investing.com Canada
Solid Biosciences chief regulatory officer Hanrahan sells $24k in SLDB stock - Investing.com Australia
Solid Biosciences COO Howton sells $43k in shares - Investing.com
Solid Biosciences (NASDAQ:SLDB) CFO Kevin Tan Sells 5,404 Shares - MarketBeat
Insider sale notice at Solid Biosciences (NASDAQ: SLDB) for RSU settlement - Stock Titan
Harahan Jessie files Form 144 to sell 4,134 SLDB shares (SLDB) - Stock Titan
Solid Biosciences supports Jett Foundation RareDiseaseDay event - Traders Union
Solid Biosciences Insiders Sold US$823k Of Shares Suggesting Hesitancy - simplywall.st
Solid Biosciences Highlights FDA Path for SGT-003 DMD Study, Shares Early Friedreich’s Ataxia Update - MarketBeat
Why is Solid Biosciences Inc. stock going upJuly 2025 Trends & Risk Managed Trade Strategies - mfd.ru
SLDB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
What analysts say about Solid Biosciences Inc. stockQuarterly Investment Review & Growth-Oriented Investment Plans - mfd.ru
Solid Biosciences (SLDB) Gets a Buy from Wedbush - The Globe and Mail
Adage discloses 1.8% Solid Biosciences (SLDB) ownership stake - Stock Titan
Citizens reiterates Market Outperform rating on Solid Biosciences stock - Investing.com Nigeria
Citizens reiterates Market Outperform rating on Solid Biosciences stock By Investing.com - Investing.com Canada
Solid Biosciences advances Duchenne treatment with FDA alignment By Investing.com - Investing.com Australia
Solid Biosciences advances Duchenne treatment with FDA alignment - Investing.com South Africa
Solid Biosciences: Positive FDA Meeting SGT-003 Sets Up Next Milestones (NASDAQ:SLDB) - Seeking Alpha
Needham Reiterates Buy Rating for Solid Biosciences (SLDB) at $1 - GuruFocus
Needham & Company LLC Reaffirms Buy Rating for Solid Biosciences (NASDAQ:SLDB) - MarketBeat
Solid Biosciences (SLDB) Gains FDA Alignment for Duchenne Trial - GuruFocus
Solid Biosciences Receives Positive FDA Feedback - Intellectia AI
Solid Biosciences To Dose First Patient In IMPACT DUCHENNE Phase 3 Trial In Q1'26 - Nasdaq
Solid Biosciences stock rises after FDA alignment on Phase 3 trial design - Investing.com Nigeria
Solid Biosciences (SLDB) Advances Duchenne Therapy with FDA Supp - GuruFocus
Solid Biosciences Inc (SLDB) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):